MGTX
NASDAQMeiraGTx Holdings plc
News · 26 weeks49+225%
2025-10-262026-04-19
Mix2690d
- Insider9(35%)
- SEC Filings8(31%)
- Other5(19%)
- M&A2(8%)
- Earnings2(8%)
Latest news
25 items- INSIDERDirector Perceptive Advisors Llc was granted 555,555 units of Ordinary Shares (SEC Form 4)4 - MeiraGTx Holdings plc (0001735438) (Issuer)
- INSIDERSEC Form 4 filed by Giroux Richard4 - MeiraGTx Holdings plc (0001735438) (Issuer)
- SECSEC Form 144 filed by MeiraGTx Holdings plc144 - MeiraGTx Holdings plc (0001735438) (Subject)
- SECSEC Form 424B5 filed by MeiraGTx Holdings plc424B5 - MeiraGTx Holdings plc (0001735438) (Filer)
- SECMeiraGTx Holdings plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - MeiraGTx Holdings plc (0001735438) (Filer)
- PRMeiraGTx Announces Pricing of $100 Million Offering of Ordinary SharesLONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten offering of 11,111,111 of its ordinary shares at an offering price of $9.00 per share. Gross proceeds to MeiraGTx from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by MeiraGTx. The Company believes that the net proceeds from this offering, together with its existing cash and cash equivalents, will be sufficient to enable it to fund its
- SECMeiraGTx Holdings plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - MeiraGTx Holdings plc (0001735438) (Filer)
- PRMeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)Company entered into an asset purchase agreement with Johnson & Johnson (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)MeiraGTx intends to immediately pursue global regulatory filings for approval of bota-vec LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that it has entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in bota-vec for the treatment of XLRP. "We are extremely pleased to have reacquired bota-vec for the treatment of XLRP,"
- SECMeiraGTx Holdings plc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - MeiraGTx Holdings plc (0001735438) (Filer)
- PRMeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced XerostomiaClinically meaningful improvements in xerostomia symptoms measured by PRO Xerostomia Questionnaire (XQ) maintained out to 3 years post treatment with AAV-hAQP1 for both bilateral and unilateral cohortsIncreases in Unstimulated Whole Saliva Flow Rate (UWSFR) maintained out to 3 yearsAAV-hAQP1 was safe and well tolerated at each dose testedAAV-hAQP1 Data presentation webcast to be held today, April 16, 2026, at 8:00 a.m. ET LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced positive three-year data from the completed Phase 1 AQUAx study of AAV-hAQP1 for the treatment
- PRMeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026- Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for both PRO and objective measures. LONDON and NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced it will host a conference call and webcast to present 3-year data from the long-term follow-up of patients in the Phase 1 study of AAV-hAQP1 for the treatment of persistent grade 2/3 moderate to severe radiation-induced xerostomia (RIX) on Thursday, April 16, 2026, at 8:00 a.m. ET. The
- INSIDERSEC Form 4 filed by Naylor Stuart4 - MeiraGTx Holdings plc (0001735438) (Issuer)
- SECSEC Form 10-K filed by MeiraGTx Holdings plc10-K - MeiraGTx Holdings plc (0001735438) (Filer)
- SECMeiraGTx Holdings plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - MeiraGTx Holdings plc (0001735438) (Filer)
- PRMeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational ResultsFDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tractMeiraGTx to hold a program update and present long-term data for AAV2-hAQP1 program for the treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16th, 2026 LONDON and NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the fourth quarter and full-year ended December 31, 2025, and provided a corporate update. "We are delighted to have been aw
- INSIDERSEC Form 4 filed by Forbes Alexandria4 - MeiraGTx Holdings plc (0001735438) (Issuer)
- SECSEC Form 144 filed by MeiraGTx Holdings plc144 - MeiraGTx Holdings plc (0001735438) (Subject)
- INSIDERCHIEF MEDICAL OFFICER Zeldin Robert K converted options into 7,500 units of Ordinary Shares and covered exercise/tax liability with 2,952 units of Ordinary Shares, increasing direct ownership by 3% to 172,888 units (SEC Form 4)4 - MeiraGTx Holdings plc (0001735438) (Issuer)
- INSIDERGENERAL COUNSEL AND SECRETARY Wollin Robert J converted options into 11,250 units of Ordinary Shares and covered exercise/tax liability with 5,949 units of Ordinary Shares, increasing direct ownership by 10% to 57,377 units (SEC Form 4)4 - MeiraGTx Holdings plc (0001735438) (Issuer)
- INSIDERCHIEF DEV. OFFICER Naylor Stuart converted options into 25,000 units of Ordinary Shares and covered exercise/tax liability with 11,750 units of Ordinary Shares, increasing direct ownership by 2% to 696,166 units (SEC Form 4)4 - MeiraGTx Holdings plc (0001735438) (Issuer)
- INSIDERCFO & COO Giroux Richard converted options into 60,000 units of Ordinary Shares and covered exercise/tax liability with 31,726 units of Ordinary Shares, increasing direct ownership by 3% to 1,027,530 units (SEC Form 4)4 - MeiraGTx Holdings plc (0001735438) (Issuer)
- INSIDERPRESIDENT & CEO Forbes Alexandria covered exercise/tax liability with 33,048 units of Ordinary Shares and converted options into 62,500 units of Ordinary Shares, increasing direct ownership by 2% to 1,511,695 units (SEC Form 4)4 - MeiraGTx Holdings plc (0001735438) (Issuer)
- PRWhy Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&AAUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), which holds multiple clinical-stage and late-stage program
- SECAmendment: SEC Form SCHEDULE 13G/A filed by MeiraGTx Holdings plcSCHEDULE 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)
- SECSEC Form SCHEDULE 13G filed by MeiraGTx Holdings plcSCHEDULE 13G - MeiraGTx Holdings plc (0001735438) (Subject)